Primary Care

Manufacturing and Regulatory Pathways of Biosimilars

As more biosimilars become available, clinicians need to be updated on what biosimilars are and the clinical, economic, and prescribing issues related to their use. In this video, Jonathan Kay, MD, and Alissa...

Naming, Switching, and Interchangeability of Biosimilars

The safety and interchangeability of biosimilars presents a growing concern for clinicians. In this video, Jonathan Kay, MD, and Alissa Segal, PharmD, discuss the naming of biosimilars, interchangeability in...

Barriers to Biosimilars Uptake in the United States

While biosimilars have the potential to lower healthcare expenditures, uptake of these agents has been slower than expected. To help remove barriers to use of these agents, Jonathan Kay, MD, and Alissa Segal,...

Why Aren't We Preventing the Preventable: Updates in Meningococcal B and Other Vaccine Hot Topics

Meningococcal disease, specifically serotype B (MnB), is an ongoing problem in this country, particularly in light of recent university outbreaks. The disease can develop from initial symptoms to death within...

Why Aren't We Preventing the Preventable: Updates in Meningococcal B and Other Vaccine Hot Topics

Massachusetts AAP Chapter Webinar

Meningococcal disease, specifically serotype B (MnB), is an ongoing problem in this country, particularly in light of recent university...